AVAH · Aveanna Healthcare Holdings

The thesis

Aveanna Healthcare's shares are modestly more likely than not to beat the S&P 500 over the next three months. On 12 November 2026 the company beat third-quarter estimates and raised its fiscal 2026 outlook for a second time, yet the shares fell to $12.24 that day. The California nursing-rate payment that starts on 1 January 2027 and the fourth-quarter report in early 2027 show whether profit keeps growing faster than revenue.

The third-quarter release on 12 November 2026 raised fiscal 2026 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance to more than $374 million, from more than $365 million. Revenue guidance rose to more than $2.695 billion, from more than $2.68 billion. A company news headline the same day put the consensus revenue estimate at $2.693 billion, so the profit raise carries most of the case.

The shares fell because the raise left little room in the fourth quarter. Raymond James calculated that the new outlook implies fourth-quarter adjusted EBITDA of more than $94.1 million, against a $95.5 million consensus, per Investing.com on 12 November 2026. On the call, management said it anchored the guide to the mid-$90 million range, with a chance of approaching $100 million. The rating is medium because the quarter beat on revenue and profit and the shares now trade near where they stood three months ago. Supply from former sponsor holders and higher hedging costs from February 2027 keep it from going higher.

Bullish and bearish views on Aveanna Healthcare Holdings Inc.

The bull case on Aveanna Healthcare Holdings Inc. (AVAH), in brief: profit growth is outpacing revenue. The bear case: the fourth-quarter guide sits below consensus.

Bull case

• Profit growth is outpacing revenue. In the quarter ended 3 October 2026, adjusted EBITDA rose 25.0% to $100.1 million on revenue up 11.8% to $695.5 million, per the 12 November 2026 release. Revenue beat a $679.5 million estimate and adjusted EBITDA beat a $93.1 million estimate, per Investing.com's report of Raymond James's note on 12 November 2026.
• The full-year outlook went up again. The 12 November 2026 release lifted fiscal 2026 adjusted EBITDA guidance to more than $374 million. The August release had already lifted it from $338–342 million to more than $365 million.
• Volume is driving growth. Private Duty Services volume grew 10% against a 7% consensus, per Raymond James on 12 November 2026. Segment revenue rose 11.6% to $574.2 million, Home Health & Hospice 15.6% to $72.1 million and Medical Solutions 9.1% to $49.2 million, per the release.
• California money arrives in January. Management said on the 12 November 2026 call that the California Department of Health Care Services (DHCS) budget includes about $30 million in state funds for private duty nursing, matched federally to about $60 million, paid as a supplement from 1 January to 30 June 2027.
• Cash generation is strong. Nine-month free cash flow was $141.2 million and cash was $197.8 million at 3 October 2026, per the release. Third-quarter net income was $45.5 million against $14.1 million a year earlier, and management cited liquidity of $492 million on the call.

Bear case

• The fourth-quarter guide sits below consensus. Raymond James put the implied fourth-quarter adjusted EBITDA at more than $94.1 million against a $95.5 million consensus on 12 November 2026. Management said fourth-quarter revenue and profit will be lower than the third quarter's because of holidays, a 14-week prior-year quarter and year-end accruals.
• Rate protection gets more expensive. At 3 October 2026 the company held interest-rate caps on the Secured Overnight Financing Rate (SOFR) of $520.0 million at 4.00% and $880.0 million at 2.96%, per the release. Management said on the call that a new $880 million cap at a 5.25% strike takes effect in February 2027.
• The California payment is temporary. DHCS treats the 2027 money as a six-month supplement on top of base rates, per the 12 November 2026 call. Management said it will not raise base nurse wages until the payment becomes permanent in the 2028 state budget.
• Debt rose during the quarter. Total debt was $1,521.3 million at 3 October 2026, up from $1,483.4 million at 4 July 2026, including $206.3 million drawn on the securitization facility, per the release. Management targets leverage below three times in 2027.
• Former sponsor holders sold heavily. SEC Form 4 filings show Robert M. Williams Jr. and Paul R. Vigano each sold 16,750,002 shares and J.H. Whitney Equity Partners VII sold 14,746,077 shares at $11.50 on 20 August 2026 and 21 August 2026. Williams and Vigano still filed as 10% owners. Chief Executive Jeff Shaner, director Rodney D. Windley and Chief Administrative Officer Edwin C. Reisz also sold at $11.50 on 20 August 2026.

Price setup

The shares closed at $12.24 on 12 November 2026, down from $13.09 on 11 November 2026, the last close before the report. Investing.com showed the day's fall at 6.49%. The 12 November 2026 close was 16.8% below the 52-week intraday high of $14.71 set on 16 September 2026. The closing low of the past year was $6.22 on 10 April 2026.

As of 12 November 2026, the 50-day moving average was $13.06 and the 200-day moving average was $9.43, from adjusted daily closes. The report-day fall took the shares below the 50-day average. They remain well above the 200-day average.

The three-month change to 12 November 2026 was −0.6%, from a close of $12.32 on 14 August 2026. Two raised outlooks in that span left the price roughly flat. The market is pricing a slower fourth quarter and sponsor supply more than the higher full-year outlook. Raymond James kept a $15.00 target on 12 November 2026.

The $11.50 price at which former sponsor holders and executives sold in August 2026, per Form 4 filings, is the main reference level below the market. The 50-day average and then the September high are the reference levels above it.

Catalysts ahead

• ~10 January 2027 (est.): California governor's budget proposal for the 2027–2028 state fiscal year. Shows whether the private duty nursing rate money becomes permanent, which management says it needs before raising base nurse wages.
• 1 January 2027: California private duty nursing supplemental payment begins, running to 30 June 2027. Starts the roughly $60 million rate supplement; first-quarter 2027 results will show how much reaches Private Duty Services revenue and margin.
• ~26 February 2027 (est.): Fourth-quarter and full-year fiscal 2026 results; the company has not announced a date. Shows whether fiscal 2026 adjusted EBITDA ends above the greater-than-$374 million outlook and sets the first 2027 guidance, which decides whether profit growth keeps outpacing revenue.

What would change the view

A daily close below $11.29, the 13 August 2026 close on the day of the second-quarter guidance raise, which would erase the gains since that raise; or fiscal 2026 adjusted EBITDA reported below $374 million.

The risks this note tracks, each with what would confirm it:

• Former sponsor holders sell more shares, adding supply regardless of operating results. Confirmed by: new Form 4 or Form 144 sale filings by Williams, Vigano or J.H. Whitney, or another secondary offering announcement.
• The fourth quarter comes in at the low end of management's range. Confirmed by: fourth-quarter adjusted EBITDA below the mid-$90 million range management cited on the 12 November 2026 call.
• California's private duty nursing money stays temporary, holding back wage investment and staffing. Confirmed by: a California budget proposal for 2027–2028 that does not make the private duty nursing rate increase permanent.
• Interest costs rise as the 5.25% cap replaces the 2.96% cap in February 2027. Confirmed by: quarterly interest expense in 2027 above the $27.1 million reported for the quarter ended 3 October 2026.
• State Medicaid budget pressure weakens the Private Duty Services business. Confirmed by: a disclosed reimbursement cut in a core state accompanied by lower company guidance.
• Borrowing keeps rising and deleveraging stalls. Confirmed by: year-end total debt above the $1,521.3 million reported at 3 October 2026, or larger draws on the securitization facility.
• The 2027 outlook implies slower growth than 2026. Confirmed by: initial 2027 adjusted EBITDA guidance at the fourth-quarter report that implies growth well below 2026's pace.

What it trades with

Aveanna trades with home and community health care providers and with small-cap, leveraged health services names. More than 80% of revenue is Medicaid-driven, per Investing.com's summary of the 16 September 2026 Deutsche Bank Healthcare Summit, so state budgets matter more than the broad market. Its term loans float with SOFR, so short-term rates still matter, more so once the 5.25% cap replaces the 2.96% cap in February 2027. Possible further sales by former sponsor holders add a supply factor that does not depend on operating results.